Abstract
A patient with homocystinuria, a risk factor of arterial and venous thrombosis, developed cerebral venous thrombophlebitis before the age of twenty years. As she was B6 sensible, she was given 250 mg/d of pyridoxine and homocysteinemia was well controlled. Unfortunately, at the age of 40, she developed progressive weakness, with a major increase of plasma CPK values (4110 UI/l, normal < 160). Severe rhabdomyolysis was observed, and muscle biopsy showed necrotic fibres. She died of pulmonary embolism. B6 vitamin is not known to be toxic. However, excessive intake can cause ataxia and severe neuropathy. But some authors have reported that a short term administration of 500 mg/d of pyridoxine to a one-month old child caused a rhabdomyolysis, and this observation might evocate a particular susceptibility of our homocystinuric patient to B6 vitamin therapy.
Keywords: Homocystinuria, homocysteine, cystathionine b-synthase, thromboembolic accident, Vitamin B6, rhabdomyolysis
Letters in Drug Design & Discovery
Title: Homocystinuric Patient with Deficient CBS Activity: Pyridoxine Efficacy and Toxicity?
Volume: 3 Issue: 2
Author(s): M. Candito, P. Dellamonica, P. Hofman and Emmanuel V. Obberghen
Affiliation:
Keywords: Homocystinuria, homocysteine, cystathionine b-synthase, thromboembolic accident, Vitamin B6, rhabdomyolysis
Abstract: A patient with homocystinuria, a risk factor of arterial and venous thrombosis, developed cerebral venous thrombophlebitis before the age of twenty years. As she was B6 sensible, she was given 250 mg/d of pyridoxine and homocysteinemia was well controlled. Unfortunately, at the age of 40, she developed progressive weakness, with a major increase of plasma CPK values (4110 UI/l, normal < 160). Severe rhabdomyolysis was observed, and muscle biopsy showed necrotic fibres. She died of pulmonary embolism. B6 vitamin is not known to be toxic. However, excessive intake can cause ataxia and severe neuropathy. But some authors have reported that a short term administration of 500 mg/d of pyridoxine to a one-month old child caused a rhabdomyolysis, and this observation might evocate a particular susceptibility of our homocystinuric patient to B6 vitamin therapy.
Export Options
About this article
Cite this article as:
Candito M., Dellamonica P., Hofman P. and Obberghen V. Emmanuel, Homocystinuric Patient with Deficient CBS Activity: Pyridoxine Efficacy and Toxicity?, Letters in Drug Design & Discovery 2006; 3 (2) . https://dx.doi.org/10.2174/157018006775789720
DOI https://dx.doi.org/10.2174/157018006775789720 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
Current Cardiology Reviews Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond
Current Pharmaceutical Design Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?
Cardiovascular & Hematological Disorders-Drug Targets Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Direct Antithrombins: New Perspectives in Cardiovascular Medicine
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Early Postoperative Bleeding in Polytrauma Patients Treated with Fondaparinux: Literature Review and Institutional Experience
Current Vascular Pharmacology Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Small Peptide Radiopharmaceuticals in the Imaging of Acute Thrombus
Current Pharmaceutical Design Molecular Imaging: Its Application In Cardiovascular Diagnosis
Current Pharmaceutical Design Subclinical Hypothyroidism and Homeostatic Disturbances: Case Report and Literature Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Turning Up the Pressure on Vascular Disease
Current Neurovascular Research The Malignant Obesity Hypoventilation Syndrome (MOHS)
Current Respiratory Medicine Reviews Lenalidomide for Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design Novel Therapeutic Agents in the Management of Hemorrhage and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets